GRI Bio (GRI) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $27.00 from $32.00 | Aug 21, 2026 |
| Ascendiant Capital | Maintained | Buy | $32.00 from $40.00 | Jun 1, 2026 |
| Ascendiant Capital | Maintained | Buy | $40.00 from $1,008.00 | Mar 11, 2026 |
| Ascendiant Capital | Maintained | Buy | $36.00 from $35.00 | Dec 8, 2025 |
| Ascendiant Capital | Maintained | Buy | $35.00 from $34.00 | Sep 22, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Jun 11, 2025 |
| Ascendiant Capital | Maintained | Buy | $34.00 from $40.00 | May 27, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Apr 14, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $10.00 | Dec 9, 2024 |
| Ascendiant Capital | Maintained | Buy | $13.00 from $12.00 | Dec 5, 2024 |
| Ascendiant Capital | Initiated Coverage | Buy | $12.00 | Oct 8, 2024 |
Frequently asked questions
Is GRI a buy, sell, or hold?
Analysts covering GRI Bio currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on GRI?
On Aug 21, 2026, Ascendiant Capital maintained GRI Bio at Buy with a price target of $27.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.